Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Japan, DyDo Pharma has launched FIRDAPSE Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton myasthenic syndrome.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharma Highlights Growth in Rare Diseases Sector
- Catalyst Pharmaceuticals price target raised to $31 from $29 at Oppenheimer
- Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
- Catalyst settlement with Teva a positive event, says BofA
- Catalyst Pharmaceuticals up 18% after resumption following Teva settlement